JP2015500212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500212A5 JP2015500212A5 JP2014543747A JP2014543747A JP2015500212A5 JP 2015500212 A5 JP2015500212 A5 JP 2015500212A5 JP 2014543747 A JP2014543747 A JP 2014543747A JP 2014543747 A JP2014543747 A JP 2014543747A JP 2015500212 A5 JP2015500212 A5 JP 2015500212A5
- Authority
- JP
- Japan
- Prior art keywords
- carbonyl
- phthalazin
- fluoro
- piperazine
- phenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 chloro, fluoro, bromo, iodo Chemical group 0.000 claims 37
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- QNKQLZIDPHLSLX-UHFFFAOYSA-N 4-[3-[4-(1-aminocyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N)CC1 QNKQLZIDPHLSLX-UHFFFAOYSA-N 0.000 claims 2
- TVWIYKCKCUIDFX-UHFFFAOYSA-N 4-[3-[4-(2,2-dimethylpropanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F TVWIYKCKCUIDFX-UHFFFAOYSA-N 0.000 claims 2
- IJSAVXZCXLCXRP-UHFFFAOYSA-N 4-[3-[4-(2-ethylbutanoyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(CC)CC)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F IJSAVXZCXLCXRP-UHFFFAOYSA-N 0.000 claims 2
- PGOSXGKZYJLWAN-UHFFFAOYSA-N 4-[3-[4-[1-(dimethylamino)cyclobutanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N(C)C)CCC1 PGOSXGKZYJLWAN-UHFFFAOYSA-N 0.000 claims 2
- XDVCDFIVFSEAIF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 XDVCDFIVFSEAIF-UHFFFAOYSA-N 0.000 claims 2
- BCFBHNMOIFYWBS-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(piperidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCCCC1 BCFBHNMOIFYWBS-UHFFFAOYSA-N 0.000 claims 2
- PHEJNKZPYQUXHV-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[1-(methylamino)cyclobutanecarbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(NC)CCC1 PHEJNKZPYQUXHV-UHFFFAOYSA-N 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- TUWZZXGAUMSUOB-UHFFFAOYSA-N benzyl piperidine-1-carboxylate Chemical compound C1CCCCN1C(=O)OCC1=CC=CC=C1 TUWZZXGAUMSUOB-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- IDXLYJQVIRPLDQ-UHFFFAOYSA-N 2-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1C#N IDXLYJQVIRPLDQ-UHFFFAOYSA-N 0.000 claims 1
- ZQTXNSWUYNTEBB-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(2-methoxyacetyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(COC)=O ZQTXNSWUYNTEBB-UHFFFAOYSA-N 0.000 claims 1
- WAQCRMFLOXJEPH-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(2-methyl-1,3-thiazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(=O)C=1N=C(SC=1)C WAQCRMFLOXJEPH-UHFFFAOYSA-N 0.000 claims 1
- YUNMCHVYEFMZIE-UHFFFAOYSA-N 2-[4-fluoro-3-[4-(5-methyl-1,2-oxazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]phthalazin-1-one Chemical compound FC1=C(C=C(ON2C(C3=CC=CC=C3C=N2)=O)C=C1)C(=O)N1CCN(CC1)C(=O)C=1C=NOC=1C YUNMCHVYEFMZIE-UHFFFAOYSA-N 0.000 claims 1
- MUWUCBFFVDRMOQ-UHFFFAOYSA-N 2-phenoxyphthalazin-1-one Chemical compound O(C1=CC=CC=C1)N1C(C2=CC=CC=C2C=N1)=O MUWUCBFFVDRMOQ-UHFFFAOYSA-N 0.000 claims 1
- MCVFOGMCFOGZNE-UHFFFAOYSA-N 3-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC(C#N)=C1 MCVFOGMCFOGZNE-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- OXZAGDCIHSWPSQ-UHFFFAOYSA-N 4-[3-(4-acetylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F OXZAGDCIHSWPSQ-UHFFFAOYSA-N 0.000 claims 1
- RSJQQCASEGSQDI-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 RSJQQCASEGSQDI-UHFFFAOYSA-N 0.000 claims 1
- LITWQHBVWSJKPY-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-5-chloro-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=C(Cl)C=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 LITWQHBVWSJKPY-UHFFFAOYSA-N 0.000 claims 1
- FEOUWECRHACLNJ-UHFFFAOYSA-N 4-[3-(4-benzoylpiperazine-1-carbonyl)-4-fluorophenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C(=O)C1=CC=CC=C1 FEOUWECRHACLNJ-UHFFFAOYSA-N 0.000 claims 1
- QGDDDEOCEHOXKJ-UHFFFAOYSA-N 4-[3-(4-tert-butylpiperazine-1-carbonyl)-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(C)(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F QGDDDEOCEHOXKJ-UHFFFAOYSA-N 0.000 claims 1
- ZJSQULBIGVRLSV-UHFFFAOYSA-N 4-[3-[4-(1-aminocyclobutanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N)CCC1 ZJSQULBIGVRLSV-UHFFFAOYSA-N 0.000 claims 1
- UFVPUCUXFUEIDV-UHFFFAOYSA-N 4-[3-[4-(2-cyclopentylacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)CC1CCCC1 UFVPUCUXFUEIDV-UHFFFAOYSA-N 0.000 claims 1
- RWQBQENZPPMPPI-UHFFFAOYSA-N 4-[3-[4-(2-cyclopropylacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)CC1CC1 RWQBQENZPPMPPI-UHFFFAOYSA-N 0.000 claims 1
- SKGRPBVRUGLOSF-UHFFFAOYSA-N 4-[3-[4-(2-ethoxyacetyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)COCC)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F SKGRPBVRUGLOSF-UHFFFAOYSA-N 0.000 claims 1
- QJQDIQKTDSBMOB-UHFFFAOYSA-N 4-[3-[4-(4,4-difluorocyclohexanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2H-phthalazin-1-one Chemical compound Fc1ccc(Oc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CCC(F)(F)CC1 QJQDIQKTDSBMOB-UHFFFAOYSA-N 0.000 claims 1
- SSVOKXAGBNLVLQ-UHFFFAOYSA-N 4-[3-[4-(4,4-difluoropiperidine-1-carbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCC(F)(F)CC1 SSVOKXAGBNLVLQ-UHFFFAOYSA-N 0.000 claims 1
- IWLJMCXJVVOBBW-UHFFFAOYSA-N 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 IWLJMCXJVVOBBW-UHFFFAOYSA-N 0.000 claims 1
- DZWVGXKLZPKLKS-UHFFFAOYSA-N 4-[3-[4-[1-(dimethylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(N(C)C)CC1 DZWVGXKLZPKLKS-UHFFFAOYSA-N 0.000 claims 1
- YGXNDLBTQGMPOV-UHFFFAOYSA-N 4-[3-[4-[3-(dimethylamino)benzoyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound CN(C)C1=CC=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=C1 YGXNDLBTQGMPOV-UHFFFAOYSA-N 0.000 claims 1
- NDEWUMPGCMVIOL-UHFFFAOYSA-N 4-[3-[4-[4-(dimethylamino)benzoyl]piperazine-1-carbonyl]-4-fluorophenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(N(C)C)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 NDEWUMPGCMVIOL-UHFFFAOYSA-N 0.000 claims 1
- ZSHQAWHQMUOABD-UHFFFAOYSA-N 4-[4-[2-fluoro-5-[(4-oxo-3h-phthalazin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]benzonitrile Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 ZSHQAWHQMUOABD-UHFFFAOYSA-N 0.000 claims 1
- YJMHEEGVFDLUFN-UHFFFAOYSA-N 4-[4-fluoro-3-(4-methylpiperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F YJMHEEGVFDLUFN-UHFFFAOYSA-N 0.000 claims 1
- PXYIFDVNUHAHEH-UHFFFAOYSA-N 4-[4-fluoro-3-(4-prop-2-enoylpiperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)C=C)CC1 PXYIFDVNUHAHEH-UHFFFAOYSA-N 0.000 claims 1
- PWJANPHHJVLKFB-UHFFFAOYSA-N 4-[4-fluoro-3-(piperazine-1-carbonyl)phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCNCC1 PWJANPHHJVLKFB-UHFFFAOYSA-N 0.000 claims 1
- LDYIPKQZQAIRTD-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(1,3-thiazole-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CSC=N1 LDYIPKQZQAIRTD-UHFFFAOYSA-N 0.000 claims 1
- XMXROHYJWCZPPL-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2,2,2-trifluoroacetyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)C(F)(F)F)CC1 XMXROHYJWCZPPL-UHFFFAOYSA-N 0.000 claims 1
- NGRBLFZCOQNFEU-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-hydroxyethyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(CCO)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F NGRBLFZCOQNFEU-UHFFFAOYSA-N 0.000 claims 1
- VODHOJPJFWVPHK-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-hydroxypropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(O)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F VODHOJPJFWVPHK-UHFFFAOYSA-N 0.000 claims 1
- MVYFDNKSMQLYJP-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(2-methylpropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C(C)C)CCN1C(=O)C1=CC(OC=2C3=CC=CC=C3C(=O)NN=2)=CC=C1F MVYFDNKSMQLYJP-UHFFFAOYSA-N 0.000 claims 1
- ZNXUITMOKZZDLO-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(3,3,3-trifluoropropanoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N1CCN(C(=O)CC(F)(F)F)CC1 ZNXUITMOKZZDLO-UHFFFAOYSA-N 0.000 claims 1
- DSBUUJLGVNOCFI-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(3-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=C1 DSBUUJLGVNOCFI-UHFFFAOYSA-N 0.000 claims 1
- GXQGLXCMWVOQCQ-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 GXQGLXCMWVOQCQ-UHFFFAOYSA-N 0.000 claims 1
- ZVASRUFHGODWNV-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C(=O)C1=CC=C(F)C=C1 ZVASRUFHGODWNV-UHFFFAOYSA-N 0.000 claims 1
- JYULXMCNNAMJSH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 JYULXMCNNAMJSH-UHFFFAOYSA-N 0.000 claims 1
- STZWABPGYDHYHM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound [O-][N+](=O)C1=CC=CC(C(NN=2)=O)=C1C=2OC(C=1)=CC=C(F)C=1C(=O)N(CC1)CCN1C1=CC=C(F)C=C1 STZWABPGYDHYHM-UHFFFAOYSA-N 0.000 claims 1
- JTZDUKTYNORBQE-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 JTZDUKTYNORBQE-UHFFFAOYSA-N 0.000 claims 1
- MYMOJTQDIFCGBT-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-5-nitro-2h-phthalazin-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C([N+]([O-])=O)C=CC=C4C(=O)NN=3)C=2)F)CC1 MYMOJTQDIFCGBT-UHFFFAOYSA-N 0.000 claims 1
- AWJBJIJKZWTVPH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(4-oxocyclohexanecarbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CCC(=O)CC1 AWJBJIJKZWTVPH-UHFFFAOYSA-N 0.000 claims 1
- DSBVAGDGCREERF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(5-methyl-1,2-oxazole-3-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound O1C(C)=CC(C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)=N1 DSBVAGDGCREERF-UHFFFAOYSA-N 0.000 claims 1
- NUSRLLJEWPPZLY-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(furan-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CO1 NUSRLLJEWPPZLY-UHFFFAOYSA-N 0.000 claims 1
- MZUSFLMKFYNSLH-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(morpholine-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCOCC1 MZUSFLMKFYNSLH-UHFFFAOYSA-N 0.000 claims 1
- PJBCOLGZCWHQBM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrazole-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1C=CC=N1 PJBCOLGZCWHQBM-UHFFFAOYSA-N 0.000 claims 1
- GTOVJKQDZATUTM-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyridine-4-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=NC=C1 GTOVJKQDZATUTM-UHFFFAOYSA-N 0.000 claims 1
- IAEWYDVKRXZOBF-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrrolidine-1-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)N1CCCC1 IAEWYDVKRXZOBF-UHFFFAOYSA-N 0.000 claims 1
- XKGULLZXZMMSTK-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(pyrrolidine-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CCCN1 XKGULLZXZMMSTK-UHFFFAOYSA-N 0.000 claims 1
- CHKWKJRVIKDBSS-UHFFFAOYSA-N 4-[4-fluoro-3-[4-(thiophene-2-carbonyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=CS1 CHKWKJRVIKDBSS-UHFFFAOYSA-N 0.000 claims 1
- BTWJXXSFLYVKGY-RUZDIDTESA-N 4-[4-fluoro-3-[4-[(2r)-2-methylpyrrolidine-2-carbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)[C@@]1(C)CCCN1 BTWJXXSFLYVKGY-RUZDIDTESA-N 0.000 claims 1
- WSYWPHSFOFNAPL-GOSISDBHSA-N 4-[4-fluoro-3-[4-[(2r)-2-phenylpropanoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1([C@H](C(=O)N2CCN(CC2)C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)C)=CC=CC=C1 WSYWPHSFOFNAPL-GOSISDBHSA-N 0.000 claims 1
- ITKLIXNMDWZJLG-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[(4-fluorophenyl)methyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CN1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 ITKLIXNMDWZJLG-UHFFFAOYSA-N 0.000 claims 1
- HNYXUAMLVLTDBI-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[1-(methylamino)cyclopropanecarbonyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1CN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CCN1C(=O)C1(NC)CC1 HNYXUAMLVLTDBI-UHFFFAOYSA-N 0.000 claims 1
- WHLJSEGNUSKGDC-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[4-(trifluoromethyl)benzoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound FC1=CC=C(OC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 WHLJSEGNUSKGDC-UHFFFAOYSA-N 0.000 claims 1
- DVBCKRUUPXUPJY-UHFFFAOYSA-N 4-[4-fluoro-3-[4-[4-methyl-3-(trifluoromethyl)benzoyl]piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=C(C(F)(F)F)C(C)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=CC=CC=C4C(=O)NN=3)C=2)F)CC1 DVBCKRUUPXUPJY-UHFFFAOYSA-N 0.000 claims 1
- KYGOXTUMVZLTJB-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-fluorobenzoyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1C(=O)N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C(Cl)C=CC=C4C(=O)NN=3)C=2)F)CC1 KYGOXTUMVZLTJB-UHFFFAOYSA-N 0.000 claims 1
- DINVORPPFQVLCT-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-fluorophenyl)piperazine-1-carbonyl]phenoxy]-2h-phthalazin-1-one Chemical compound C1=CC(F)=CC=C1N1CCN(C(=O)C=2C(=CC=C(OC=3C4=C(Cl)C=CC=C4C(=O)NN=3)C=2)F)CC1 DINVORPPFQVLCT-UHFFFAOYSA-N 0.000 claims 1
- VQHPTVHDNVWZCW-UHFFFAOYSA-N 5-chloro-4-[4-fluoro-3-[4-(4-nitrobenzoyl)piperazine-1-carbonyl]phenoxy]-2H-phthalazin-1-one Chemical compound [O-][N+](=O)c1ccc(cc1)C(=O)N1CCN(CC1)C(=O)c1cc(Oc2n[nH]c(=O)c3cccc(Cl)c23)ccc1F VQHPTVHDNVWZCW-UHFFFAOYSA-N 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 150000001356 alkyl thiols Chemical class 0.000 claims 1
- PTJNLVIILOMOGI-UHFFFAOYSA-N benzyl 2-[4-[2-fluoro-5-[(4-oxo-2,3-dihydro-1,8-naphthyridin-1-yl)oxy]benzoyl]piperazine-1-carbonyl]pyrrolidine-1-carboxylate Chemical compound C(C1=CC=CC=C1)OC(=O)N1C(CCC1)C(=O)N1CCN(CC1)C(C1=C(C=CC(=C1)ON1CCC(C2=CC=CN=C12)=O)F)=O PTJNLVIILOMOGI-UHFFFAOYSA-N 0.000 claims 1
- RSEPHCRIRACQML-UHFFFAOYSA-N benzyl piperidine-2-carboxylate Chemical compound C1CCCNC1C(=O)OCC1=CC=CC=C1 RSEPHCRIRACQML-UHFFFAOYSA-N 0.000 claims 1
- DMFIILJDODEYHQ-UHFFFAOYSA-N benzyl piperidine-3-carboxylate Chemical compound C1CCNCC1C(=O)OCC1=CC=CC=C1 DMFIILJDODEYHQ-UHFFFAOYSA-N 0.000 claims 1
- BLBHAAHASZMYPI-UHFFFAOYSA-N benzyl piperidine-4-carboxylate Chemical compound C1CNCCC1C(=O)OCC1=CC=CC=C1 BLBHAAHASZMYPI-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 208000028466 reproductive system neoplasm Diseases 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110390364 | 2011-11-30 | ||
| PCT/CN2012/001611 WO2013078771A1 (zh) | 2011-11-30 | 2012-12-03 | 一种多聚（adp-核糖）聚合酶抑制剂 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500212A JP2015500212A (ja) | 2015-01-05 |
| JP2015500212A5 true JP2015500212A5 (enExample) | 2015-03-26 |
| JP5820081B2 JP5820081B2 (ja) | 2015-11-24 |
Family
ID=48491227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543747A Active JP5820081B2 (ja) | 2011-11-30 | 2012-12-03 | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9187430B2 (enExample) |
| EP (1) | EP2799435B1 (enExample) |
| JP (1) | JP5820081B2 (enExample) |
| CN (1) | CN103130723B (enExample) |
| CA (1) | CA2857405C (enExample) |
| WO (1) | WO2013078771A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| MX364895B (es) | 2013-03-13 | 2019-05-10 | Forma Therapeutics Inc | Nuevos compuestos y composiciones para la inhibicion de fasn. |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| CN105017140B (zh) * | 2014-04-28 | 2017-12-29 | 复旦大学 | 邻氨基苯甲酰胺化合物及其制备方法和用途 |
| WO2015179559A2 (en) * | 2014-05-21 | 2015-11-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| CN105777651A (zh) * | 2015-01-13 | 2016-07-20 | 江苏豪森药业集团有限公司 | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 |
| US10519134B2 (en) | 2015-11-20 | 2019-12-31 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017087858A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| WO2017096315A1 (en) | 2015-12-02 | 2017-06-08 | The Scripps Research Institute | TRIAZOLE DAGL(α) INHIBITORS |
| CN107955001A (zh) * | 2016-10-14 | 2018-04-24 | 上海汇伦生命科技有限公司 | 抗肿瘤杂环并咪唑类化合物的药用盐 |
| CN106946792B (zh) * | 2017-03-29 | 2019-07-26 | 深圳市坤健创新药物研究院 | 一种酞嗪酮的异羟肟酸衍生物及其制备方法与应用 |
| CN107082764B (zh) * | 2017-05-23 | 2018-11-02 | 上海锐聚恩新药研发有限公司 | 一类多羟基酞嗪酮化合物、其制备方法及应用 |
| JOP20190267A1 (ar) | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| MY200738A (en) | 2017-05-23 | 2024-01-13 | H Lundbeck As | Pyrazole magl inhibitors |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| CA3099431A1 (en) | 2018-05-24 | 2019-11-28 | Novartis Ag | Automatic drug delivery device |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) * | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| KR102913343B1 (ko) | 2020-04-21 | 2026-01-15 | 아이디언스 주식회사 | 프탈라지논 화합물의 결정형 |
| WO2021214502A1 (en) | 2020-04-21 | 2021-10-28 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| CN111732844A (zh) * | 2020-07-08 | 2020-10-02 | 高雪梅 | 一种家居防火涂料及其制备方法 |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| US12666232B2 (en) | 2020-12-18 | 2026-06-23 | Novartis Ag | Communication module for an autoinjector |
| CN117897380A (zh) * | 2021-08-17 | 2024-04-16 | 益方生物科技(上海)股份有限公司 | 哒嗪酮或吡啶酮化合物、其制备方法和用途 |
| WO2023192864A2 (en) * | 2022-03-28 | 2023-10-05 | Oregon Health & Science University | Covalent parp16 inhibitors |
| WO2023192989A2 (en) * | 2022-04-01 | 2023-10-05 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
| TW202430518A (zh) * | 2023-01-06 | 2024-08-01 | 大陸商齊魯製藥有限公司 | Parp7抑制劑的製備方法 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| DK0841924T3 (da) * | 1995-08-02 | 2003-02-10 | Univ Newcastle Ventures Ltd | Benzimidazolforbindelser |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| DK1133477T3 (da) | 1998-11-27 | 2004-06-21 | Abbott Gmbh & Co Kg | Substituerede benzimidazoler og deres anvendelse som parpinhibitorer |
| DE19921567A1 (de) * | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| GB0026505D0 (en) | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| KR100957516B1 (ko) * | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2ｈ-프탈라진-1-온 및 이것의 사용 방법 |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| DE60335359D1 (de) * | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| WO2003103666A2 (en) | 2002-06-07 | 2003-12-18 | Altana Pharma Ag | Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones |
| CN100390164C (zh) | 2002-10-01 | 2008-05-28 | 三菱制药株式会社 | 异喹啉化合物及其医药用途 |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
| WO2005023246A1 (en) | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
| SG150548A1 (en) | 2003-12-01 | 2009-03-30 | Kudos Pharm Ltd | Dna damage repair inhibitors for treatment of cancer |
| CN1905864B (zh) | 2003-12-01 | 2011-04-06 | 库多斯药物有限公司 | 用于治疗癌症的dna损伤修复抑制剂 |
| JP4806353B2 (ja) | 2003-12-05 | 2011-11-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン |
| JP5100376B2 (ja) | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| KR20070057859A (ko) | 2004-08-26 | 2007-06-07 | 쿠도스 파마슈티칼스 리미티드 | 4-헤테로아릴메틸 치환된 프탈라지논 유도체 |
| GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| CA2580833C (en) | 2004-09-22 | 2010-12-21 | Pfizer, Inc. | Method of preparing poly(adp-ribose) polymerases inhibitors |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| JP5271897B2 (ja) | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体 |
| GB0615809D0 (en) | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| US8383623B2 (en) | 2010-04-16 | 2013-02-26 | Abbott Laboratories | Phthalazin-(2H)-one inhibitors of kinases |
| WO2012014221A1 (en) * | 2010-07-27 | 2012-02-02 | Cadila Healthcare Limited | Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
| CN103130723B (zh) * | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
-
2012
- 2012-11-30 CN CN201210504537.2A patent/CN103130723B/zh active Active
- 2012-12-03 WO PCT/CN2012/001611 patent/WO2013078771A1/zh not_active Ceased
- 2012-12-03 US US14/361,698 patent/US9187430B2/en active Active
- 2012-12-03 CA CA2857405A patent/CA2857405C/en active Active
- 2012-12-03 JP JP2014543747A patent/JP5820081B2/ja active Active
- 2012-12-03 EP EP12852659.7A patent/EP2799435B1/en active Active
-
2015
- 2015-08-13 US US14/826,181 patent/US9718787B2/en active Active